Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCTs031250279) titled 'Efficacy and safety of corticosteroid-dupilumab combination therapy for IgG4-Related Disease complicated by allergic disease' on Aug. 5.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Furuta Shunsuke
Condition:
Immunoglobulin G4-Related Disease complicated by allergic disease.
D000077733
Intervention:
Start corticosteroid on Day 1, add Dupilumab by Day 14, and continued for the 52 weeks.
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 05/08/2025
Target Sample Size: 15...